N
Nina Kola
Researcher at Bristol-Myers Squibb
Publications - 2
Citations - 1498
Nina Kola is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 1058 citations.
Papers
More filters
Journal ArticleDOI
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. Johnson,Justin M. Balko,Margaret L. Compton,Spyridon Chalkias,Joshua M. Gorham,Yaomin Xu,Mellissa Hicks,Igor Puzanov,Matthew R Alexander,Tyler L. Bloomer,Jason R Becker,David Slosky,Elizabeth J. Phillips,Mark A. Pilkinton,Laura Deeanne Craig-Owens,Nina Kola,Gregory E. Plautz,Daniel Reshef,Jonathan S. Deutsch,Raquel P. Deering,Benjamin A. Olenchock,Andrew H. Lichtman,Dan M. Roden,Christine E. Seidman,Christine E. Seidman,Igor J. Koralnik,Jonathan G. Seidman,Robert D. Hoffman,Janis M. Taube,Luis A. Diaz,Robert A. Anders,Jeffrey A. Sosman,Javid Moslehi +32 more
TL;DR: Patients with melanoma in whom fatal myocarditis developed after treatment with ipilimumab and nivolumab were having a rare, potentially fatal, T-cell-driven drug reaction, according to Pharmacovigilance studies.
Journal ArticleDOI
Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer.
Yan Zhang,Charlotte R. Doran,Trong Kim Le,Brian Dreyfus,Nina Kola,Brooke E. Sylvester,Lincy S. Lal,John R. Penrod,Stephanie Meadows Shropshire +8 more
TL;DR: In this paper , the authors describe the relationship between baseline immunosuppressive drug (ISD)/corticosteroid (CS) use, as well as the incidence of mild/moderate adverse events (AEs), and the clinical effectiveness of PD-(L)-1 blockade.